Nanoviricides (NNVC) revenue and earnings history
Nanoviricides reported revenue of $0 for fiscal 2026 (year ended Jun 30, 2026), and net income of −$8.22M.
Revenue and net income, 20 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026ended Jun 30, 2026 | $0 | −$8.31M | −$8.22M | −$7.7M | $84K | −$7.78M | — | — | — | $2.79M | — | 10-K |
| 2025ended Jun 30, 2025 | $0 |
The latest quarter, insider trades and fund moves: Nanoviricides (NNVC) on OQRO.
Common questions
What was Nanoviricides's revenue in fiscal 2026?
$0 for the year ended Jun 30, 2026, as reported in its 10-K filed Sep 28, 2026.
Has Nanoviricides been profitable?
It reported a net loss in 20 of the years shown (2006, 2007, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026). The highest net income was −$2.2M in fiscal 2015.
What was Nanoviricides's free cash flow in fiscal 2026?
−$7.78M: operating cash flow of −$7.7M minus capital expenditure of $84K. OQRO calculates free cash flow this way from the two filed lines.
Where these figures come from
The SEC’s companyfacts data: every figure Nanoviricides tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.